Tissue factor targeted antibodies as anticoagulants

Details Tissue factor targeted antibodies as anticoagulants Tissue factor targeted antibodies as anticoagulants

2004-04-30

2009-08-25

Szperka, Michael (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S145100, C424S146100, C424S133100, C424S134100, C424S141100, C530S387300, C530S388250

Reexamination Certificate

active

07579000

ABSTRACT:
This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

REFERENCES:
patent: 4208479 (1980-06-01), Zuk et al.
patent: 4912207 (1990-03-01), Majerus
patent: 5256770 (1993-10-01), Glaser
patent: 5298599 (1994-03-01), Rezaie
patent: 5466668 (1995-11-01), Glaser
patent: 5506134 (1996-04-01), Soule
patent: 5574007 (1996-11-01), Zushi
patent: 5589173 (1996-12-01), O'Brien
patent: 5827824 (1998-10-01), Light
patent: 5843442 (1998-12-01), Soule et al.
patent: 5863760 (1999-01-01), Light
patent: 5874407 (1999-02-01), Kelley
patent: 5916874 (1999-06-01), Fujiwara
patent: 5986065 (1999-11-01), Wong
patent: 6063763 (2000-05-01), Light
patent: 6274142 (2001-08-01), O'Brien
patent: 6555319 (2003-04-01), Wong
patent: 6632791 (2003-10-01), Light
patent: 2008/0019985 (2008-01-01), Light
patent: 2008/0020965 (2008-01-01), Light
patent: WO88/07543 (1988-10-01), None
patent: WO 88/09811 (1988-12-01), None
patent: WO 90/10081 (1990-09-01), None
patent: WO98/40408 (1998-09-01), None
patent: WO01/70984 (2001-09-01), None
patent: WO 01/98352 (2001-12-01), None
patent: WO03/037911 (2003-05-01), None
Heyman et al., J. Immunol. 1985, 134:4018-4023.
Chapman et al., Nature Biotechnology, 1999, 17:780-783.
Harlow et al. Antibodies, A Laboratory Manual, 1988, Cold Spring Harbor Laboratory, pp. 340-341.
Adams et al., “Thrombin-cofactor Interactions: structural Insights into Regulatory Mechanisms,”Arteriosclerosis, Thrombosis, and Vascular Biology 26, 1738-45, May 25, 2006.
Amit et al., 1986,Science 233, 747-53.
Bitonti et al., Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-human Primates Through an Immunoglobulin Transport Pathway,Proc. Natl. Acad. Sci. USA 101, 9763-68, Jun. 29, 2004.
Clarke et al., The Short Loop Between epidermal Growth Factor-like Domains 4 and 5 is Critical for Human Thrombomodulin Function,J. Biol. Chem. 268, 6309-15, Mar. 25, 1993.
Dahlback et al., “Blood Coagulation,”The Lancet 355, 1627-32, May 6, 2000.
Dong et al., “P-selectin-targeting of the Fibrin Selective Thrombolytic Desmodus Rotundus Salivary Plasminogen Activator α1,”Thrombl Haemost. 92, 956-65, 2004.
Esmon, “Regulation of Blood Coagulation,”Biochim. Biophys. Acta 1477, 349-60, 2000.
Esmon, “The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation,”J. Biol. chem. 264, 4743-4846, 1989.
Faelber et al., “The 1.85 Å Resolution Crystal Structures of Tissue factor in Complex with Humanized Fab D3h44 and of Free Humanized Fab D3h44: Revisiting the Solvation of antigen combining Sites,”J. Mol. Biol. 313, 83-97, 2001.
Fuentes-Prior et al., “Structural Basis for the anticoagulant Activity of the Thrombin-thrombomodulin Complex,”Letters to Nature 404, 518-25, Mar. 30, 2000.
Gresele et al., “Novel Approaches to the Treatment of Thrombosis,”Tresnds Pharmacol. Sci. 23, 25-32, 2002.
Haber et al., “Antibody Targeting as a Thrombolytic strategy,”Ann. NY Acad. Sci. 667, 365-81, 1992.
Hall et al., “Thrombin Interacts with Thrombomodulin, Protein C, and Thrombin-activatable Fibrinolysis Inhibitor via Specific and Distinct Domains,”J. Biol. Chem. 274, 22510-16, Sep. 3, 1999.
Janeway et al.,Immunobiology, 3rded., Garland Publishin Inc., 1997, pp. 3:7-3:9.
Moons et al., “Tissue Factor and Coronary Artery Disease,”Cardiovascular Res. 53, 313-25, 2002.
Nagashima et al., “Alanine-scanning Mutagenesis of the epidermal Growth Factor-like Domains of Human Thrombomodulin Identifies Critical Residues for its Cofactor Activity,”J. Biol. Chem. 268, 2888-92, Feb. 5, 1993.
On-line Medical dictionary definition of synergy, downloaded Oct. 26, 2006 from cancerweb.ncl.ac.uk, 1 page.
Rudikoff et al.,Proc. Natl. Acad. Sci. USA 79, 1979-83, 1982.
Skolnick et al.,Trends in Biotechnology 18, 34-39, 2000.
Stedman's Medical dictionary, 27thed., 2000, definition of synergism, downloaded Oct. 26, 2006 from thomsonhc.com, 2 pages.
Wang et al., “Elements of the Primary Structure of thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation,”J. Biol. Chem. 275, 22942-47, Jul. 28, 2000.
Whisstock et al.,Quarterly Review of Biophysics 36, 307-40, 2003.

Affiliated with

Also associated with

Rating

Tissue factor targeted antibodies as anticoagulants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue factor targeted antibodies as anticoagulants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue factor targeted antibodies as anticoagulants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4122934